Factors affecting residual platelet aggregation in prasugrel treated patients

Current Pharmaceutical Design

Volumn 19, Issue 28, 2013, Pages 5121-5126

  Alexopoulos, Dimitrios ^a   Xanthopoulou, Ioanna ^a   Perperis, Angelos ^a   Siapika, Argyro ^a   Stavrou, Katerina ^a   Tsoni, Evropi ^a   Davlouros, Periklis ^a   Hahalis, George ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Pharmacodynamics; Platelet pharmacology; Platelet reactivity; Prasugrel

Indexed keywords

PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DRUG RESPONSE; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAINTENANCE DRUG DOSE; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; PLATELET REACTIVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ACUTE CORONARY SYNDROME; AGED; BLOOD PLATELETS; COHORT STUDIES; DRUG RESISTANCE; FEMALE; HEART DISEASES; HEMORRHAGE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYOCARDIAL ISCHEMIA; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; SMOKING; THIOPHENES;

EID: 84881327942     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990002     Document Type: Article

References (37)

1. Aradi D, Komocsi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010; 160: 543-551.
2. Würtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des 2012; 18: 5344-61.
3. rd, Michelson AD, Wiviott SD, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219-26
4. Geisler T, Grass D, Bigalke B, et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008; 6: 54-61
5. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427-34
6. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-57
7. Alexopoulos D, Dimitropoulos G, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011; 4: 403-10
8. Alexopoulos D, Xanthopoulou I, Panagiotou A, et al. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis. Am J Kidney Dis 2012; 59: 469-71.
9. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29: 21-30.
10. Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLE TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-32.
11. Alexopoulos D. Prasugrel resistance: fact or fiction. Platelets 2012; 23: 83-90.
12. Grove EL, Storey RF, Würtz M. Platelet function testing in atherothrombotic disease. Curr Pharm Des 2012; 18: 5379-91.
13. Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The 5126andomized, double-blind ACAPULCO study. Thromb Haemost 2010; 103: 213-23.
14. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizinganti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 trial. Eur Heart J 2011; 32: 838-46.
15. Gurbel PA, Erlinge D, Ohman EM, et al; for the TRILOGY ACS Platelet Function Substudy Investigators. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy. JAMA 2012 Nov 4: 1-10. DOI: 10.1001/jama.2012.17312. [Epub ahead of print]
16. Alexopoulos D, Panagiotou A, Xanthopoulou I, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost 2011; 9: 2379-85
17. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 2012; 59: 2159-64
18. Collet JP, Cuisset T, Rangé G, et al. the ARCTIC Investigators. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med 2012 Nov 4. DOI 10.1056/NEJMoa1209979 [Epub ahead of print]
19. Li YG, Ni L, Brandt JT, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets 2009; 20: 316-27
20. Small DS, Farid NA, Payne CD, et al. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet 2010; 49: 777-98
21. Cayla G, Cuisset T, Silvain J, et al. Prasugrel Monitoring and Bleeding in Real World Patients. Am J Cardiol 2012 Oct 2. DOI: pii: S0002-9149(12)02060-7. 10.1016/j.amjcard.2012.08.043. [Epub ahead of print]
22. Alexopoulos D, Xanthopoulou I, Davlouros P, et al. Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel. Am Heart J 2011; 162: 733-9.
23. Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high onclopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 2012; 60: 193-9.
24. Alexopoulos D, Theodoropoulos KC, Stavrou EF, et al. Prasugrel Versus High Dose Clopidogrel to Overcome Early High on Clopidogrel Platelet Reactivity in Patients with ST Elevation Myocardial Infarction. Cardiovasc Drugs Ther 2012; 26: 393-400
25. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST elevation myocardial infarction. Circ Cardiovasc Interv 2012; 5(6): 797-804
26. Alexopoulos D, Xanthopoulou I, Mavronasiou E, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes mellitus. Diabetes Care 2013 Mar 14. doi: 10.2337/dc12-2510 [Epub ahead of print]
27. Brar SS, Ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-54
28. Ferreiro JL, Sibbing D, Angiolillo DJ. Platelet function testing and risk of bleeding complications. Thromb Haemost 2010 Jun; 103(6): 1128-35.
29. Silvain J, Cayla G, Hulot JS, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J 2012; 33: 1241-9
30. Michelson AD, Linden MD, Furman MI, et al. Evidence that preexistent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost 2007; 5: 75-81
31. D. Alexopoulos, I. Xanthopoulou, P. Davlouros, et al. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel and ticagrelor treated patients. J Thromb Haemost 2013; 11: 38-4.
32. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, Ring BJ. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006; 34: 600-7
33. Gurbel PA, Bliden KP, Logan DK, et al. The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study. J Am Coll Cardiol 2013 Apr 16 doi: pii: S0735-1097(13)01478-2. 10.1016/j.jacc.2013.03.037. [Epub ahead of print]
34. Washio I, Maeda M, Sugiura C, et al. Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes. Drug Metab Dispos 2011; 39: 1-3.
35. Cuisset T, Gaborit B, Dubois N, et al. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. Int J Cardiol 2012 Oct 16 DOI: pii: S0167-5273(12)01335-6. 10.1016/j.ijcard.2012.09.214. [Epub ahead of print]
36. Parodi G, Bellandi B, Venditti F, et al. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. Am J Cardiol 2012; 109: 214e218
37. Cuisset T, Loosveld M, Morange PE, et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc Interv 2012; 5: 1280-7.